Please assess the completion status of the following clinical trial:

Trial Title: Everolimus Versus Placebo in Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Squamous cell carcinoma of the head and neck (stage IVa or IVb). No evidence (absence)of disease by scan.~* 18 years or older.~* Performance status 70% or better.~* Adequate marrow, renal and liver function (will be tested by labs). _ Able give consent.~Exclusion Criteria:~* Currently receiving anti-cancer treatment.~* Major surgery or traumatic injury within 4 weeks.~* Radiotherapy related toxicities.~* Lip, nasopharynx, nasal cavity, paranasal sinus, salivary gland, skin, or thyroid primary tumors~* Receiving other investigational drugs.~* Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent.~* Receive immunization with attenuated live vaccines (seasonal flu shot)1 week before starting this .~* Show evidence of disease (cancer).~* Uncontrolled medical conditions such as: unstable angina, congestive heart failure, diabetes, severely impaired lung function.~* Liver disease such as cirrhosis, severe hepatic impairment, Hepatitis B or C.~* Active, uncontrolled severe infections~* Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.~* Known History of HIV positivity.~* Impaired gastrointestinal function that may alter absorption of Everolimus such as ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection.~* Patients with an active, bleeding diathesis.~* Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. )~* Male patient whose sexual partner(s) are Women of child bearing potential who are not willing to use adequate.~contraception, during the study and for 8 weeks after the end of treatment~* Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).~* Patients with a known hypersensitivity to Everolimus or other rapamycin analogues (sirolimus, temsirolimus) or to its excipients.~* History of noncompliance to medical regimens.~* Patients unwilling to or unable to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (RAD001) (Type: EXPERIMENTAL): Subjects will receive Everolimus 10 mg daily
- Placebo (Type: EXPERIMENTAL): Subjects will receive double-blind placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).